The global demand for PD1/PDL1 inhibitors has been marginally impacted by the coronavirus pandemic in 2020, with disruptions and delays in supply chains owing to logistical and transport issues. According to a recent study by Future Market Insights (FMI), the long-term prospects of the industry is likely to remain very positive, with investments growing for cancer treatment research and emphasis on biologics in the pharma industry.
According to FMI analysts, PD1/PDL1 inhibitors are anticipated to play increasingly important roles in cancer treatment procedures, owing to lower toxicity levels in comparison to other treatment alternatives, and better compliance with safety standards being implemented by regulatory bodies in different countries.
To remain ‘ahead’ of your competitors, request for a sample
The industry has witnessed exponential growth in the past few years on account of investments into research for biologics in the pharmaceutical sector and the potential application of immunity check point inhibitors, and promising results from clinical trials against conditions such as non-small cell lung cancer, melanoma, and head & neck squamous cell cancer among others.
Pembrolizumab and nivolumab inhibitors are being used increasingly in the healthcare sector owing to regulatory approval for treating a wider range of cancers in comparison to other PD1/PDL1 inhibitor variants. Applications towards treating non-small cell lung cancer will remain a major contributor to industry revenues.
However, high costs associated to cancer treatment in hospital settings, coupled with long durations and strict regulations associated with the approval process of PD1/PDL1 inhibitor products are major challenges to market participants.
The report by FMI offers a detailed market overview, covering critical growth dynamics. Some of the top takeaways from the study include:
The PD1/PDL1 inhibitors Market was valued at US$ 21.8 Bn in 2019, with growth diminishing slightly during the coronavirus crisis
Pembrolizumab inhibitors remain in high demand owing to regulatory approval for applications for a wider range of cancer treatments
Sales and distribution through hospital pharmacies will remain higher than retail and online pharmacy alternatives, owing to robust supply chains and larger inventories
Sales in North America will remain critical to market growth through 2030. However, Asian countries are reflecting lucrative growth opportunities with a vast population base and investments in healthcare infrastructure modernization
“PD1/PDL1 inhibitors are a number of fairly new checkpoint inhibitor cancer treatment drugs which block select immune checkpoint proteins in cells that are at risk to tumours and are emerging as a front-line treatment in immunotherapy for several types of cancer, driven by healthcare research in North America and Europe,” said a lead analyst at FMI.
Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-12644
Covid-19 Impact on the PD1/PDL1 Inhibitors Market
The coronavirus pandemic is estimated to have a moderate impact on the PD1/PDL1 inhibitors market in the short term. Challenges are likely to arise in terms of supply chain disruptions in terms of raw materials and product delivery owing to logistical and transportation delays.
Further, governments and healthcare facilities around the world are redirecting essential resources towards handling the pandemic, which is limiting the scope of application for cancer treatments through PD1/PDL1 inhibitors.
The uncertainty over the duration and the severity of the pandemic is a key challenge that players in the PD1/PDL1 inhibitors market will have to contend with in the months to come. However, the higher risk of comorbidities for cancer patients also affected by the coronavirus is expected to partially alleviate challenges in the industry. Recovery of the sector is likely to be strong as cancer cases remain prevalent across the globe.
Who is Winning?
In the report, FMI has scrutinized the different strategies businesses involved in the PD1/PDL1 inhibitors market have employed. Top players in the industry have largely invested in product development and research efforts including major clinical trials. Also, capacity expansions along with strategic partnerships and acquisitions have gained importance among the market players.
Some of the leading players in the PD1/PDL1 inhibitors market include
Bristol-Myers Squibb
Merck & Co. Inc.
F. Hoffmann-La Roche AG
Merck KGaA
Pfizer Inc.
and AstraZeneca.
Key Segments
Product type
Nivolumab
Pembrolizumab
Atezolizumab
Avelumab
Durvalumab
Indication
Melanoma
Non-Small Cell Lung Cancer (NSCLC)
Renal Cell Carcinoma (RCC)
Head and Neck Squamous Cell Cancer (HNSCC)
Bladder Cancer
Merkel Cell Carcinoma (MCC)
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-12644
Regional Outlook
North America (U.S., Canada)
Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
Europe (Germany, Italy, France, U.K., BENELUX, Spain, Russia, Rest of Europe)
South Asia (India, Thailand, Indonesia, Malaysia, Rest of South Asia)
East Asia (China, Japan, South Korea)
Oceania (Australia, New Zealand)
Middle East & Africa (GCC Countries, Turkey, South Africa, Rest of MEA)